According to the new market research report, "Peptide Synthesis Market by Reagent (Resins, Amino Acid, Dyes), Equipment (Peptide Synthesizer, Chromatography, Lyophilizer), Technology (Solid-phase, Solution-phase, Hybrid & Recombinant), End User (Pharma, Biotech, CRO) - Global Forecast to 2026" The global peptide synthesis market is projected to USD 730 million by 2026 from USD 515 million in 2021, at a CAGR of 7.2 % between 2021 and 2026.

Global Industry Growth Boosting Factors:

Growth in this market is driven by the increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced automated peptide synthesizers. Increasing R&D activities indicate the gradual development of a robust research base globally. However, the lack of a unified set of regulations for therapeutic peptides and the high cost of instruments are expected to restrain the growth of this market during the forecast period.

Overview:

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global peptide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

DRIVER:Increasing use of peptides in pharmaceutical drugs

Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity.Oncology, diabetes, and obesity are three prominent therapeutic areas where peptides generate billions of dollars in revenues.

The demand for peptides is also increasing for the treatment of cardiovascular and neurodegenerative diseases, renal failure, and rare diseases. Currently, there are more than 100 FDA-approved peptide-based drugs on the market. This number is expected to grow significantly, with approximately 700 peptide drugs and therapeutic peptides currently in clinical trials in preclinical development

RESTRAINT:Lack of a unified set of regulations for therapeutic peptides

Peptide-based drugs fall in the range of small-molecule and large-molecule biologics. Being at the borderline between typical small molecules and large proteins, peptides have raised a series of regulatory challenges. Most of these drugs are chemically synthesized. Though the synthesis process for different peptide drugs is similar, their action mechanisms vary widely. Hence, developing a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task. There are no formal guidelines from any regulatory agency for developing this class of therapeutics.

OPPORTUNITY:Development of personalized medicines

Interest in personalized treatment has been fueled by the concept of tailored therapy with the best response and highest safety margin to ensure better patient care. Proteomic analysis is an attractive and powerful tool for characterizing the molecular profiles of various tissues, either in the normal or diseased state. Personalized proteomics or proteomic profiling is the next big step in personalized medicine; it provides clarity on disease pathomechanisms.

To boost the use of proteomics in personalized medicine, scientists proposed the development of a user-friendly platform to program electrochemically directed peptide synthesis based on a microfluidic multiplexing system controlled by software under the ElectroMed project funded by the European Union. The ligand-receptor complexes will then be detected and quantified by label-free sensors based on nanomaterials. The system will enable an automated injection of the different reagents needed for the ligand synthesis for the personalized and controlled synthesis of peptides, making possible the use of proteomics for personalized medicine.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

CHALLENGE: Issues associated with the route of administration of peptide drugs

The majority of therapeutic peptides are administered by the parenteral route because of insufficient absorption from the gastrointestinal tract. Peptide drugs are usually indicated for chronic conditions, and the use of injections on a daily basis during long-term treatment has significant drawbacks. In contrast to this inconvenient and potentially problematic method of drug administration, the oral route offers advantages such as self-administration with a high degree of patient acceptability and compliance. The main reasons for the low oral bioavailability of peptide drugs are pre-systemic enzymatic degradation and poor penetration of the intestinal mucosa.

Also, these therapeutics tend to have a high molecular weight, low lipophilicity, and charged functional groups that hamper their absorption. These characteristics lead to the low bioavailability of most orally administered peptides and short half-lives. Intravenous or subcutaneous delivery of these therapeutics overcomes the issue of absorption, but other factors limit the bioavailability of peptide and protein therapeutics, including systemic proteases, rapid metabolism, opsonization, conformational changes, dissociation of subunit proteins, non-covalent complexation with blood products, and destruction of labile side-groups.